본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Journal of gynecologic oncology : jgo 17건

  1. [국내논문]   A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses   SCIE

    Bogani, Giorgio (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Tagliabue, Elena (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Signorelli, Mauro (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Ditto, Antonino (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Martinelli, Fabio (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Chiappa, Valentina (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Mosca, Lavinia (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Sabatucci, Ilaria (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Leone Roberti Maggiore, Umberto (Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy . ) , Lorusso, Domenica , Raspagliesi, Francesco
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e40 , 2018 , 2005-0380 ,

    초록

    Objective To test the applicability of the Arbeitsgemeinschaft GynAkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC). Methods Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft GynAkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS. Results Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857). Conclusion The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [국내논문]   Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer   SCIE

    Takeda, Takashi (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Tsuji, Kosuke (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Banno, Kouji (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Yanokura, Megumi (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Kobayashi, Yusuke (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Tominaga, Eiichiro (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . ) , Aoki, Daisuke (Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan . )
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e29 , 2018 , 2005-0380 ,

    초록

    Objective Lynch syndrome is a cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes. Lynch syndrome only causes about 0.4% of cases of ovarian cancer, which suggests that universal screening may not be cost-efficient. However, the frequency of Lynch syndrome in ovarian cancer is unclear in the Asian population. The goal of the study was to investigate a screening strategy using family history. Methods The subjects were 129 patients with ovarian cancer. Clinical and family history were collected using a self-administered questionnaire, and Society of Gynecologic Oncology (SGO) criteria 2007 and PREMM 5 were used for risk assessment. Microsatellite instability, immunohistochemistry, and methylation of MMR genes were analyzed. Results Of the 129 cases, 25 (19.4%) met the SGO criteria, and 4 of these 25 had MSI-high and MMR deficiency. Two cases had loss of MSH2 and MSH6, indicating MSH2 mutation, and the other two had loss of MLH1 and PMS2, including one without MLH1 methylation indicating MLH1 mutation. These results show that screening using family history can detect Lynch syndrome in 12.0% (3/25) of ovarian cancer cases. The 3 cases were positive for PREMM 5 , but negative for Amsterdam II criteria and revised Bethesda guidelines. Genetic testing in one case with MSH2 and MSH6 deficiency confirmed the diagnosis of Lynch syndrome with MSH2 mutation. Conclusion This is the first study of screening for Lynch syndrome in ovarian cancer using clinical and family history in an Asian population. This approach may be effective for diagnosis in these patients.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [국내논문]   Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer   SCIE

    Hirose, Sou (Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa, Japan . ) , Tanabe, Hiroshi (Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa, Japan . ) , Nagayoshi, Youko (Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan . ) , Hirata, Yukihiro (Department of Obstetrics and Gynecology, The Jikei University Katsushika Medical Center, Tokyo, Japan . ) , Narui, Chikage (Department of Obstetrics and Gynecology, The Jikei University Daisan Hospital, Tokyo, Japan . ) , Ochiai, Kazuhiko (Department of Obstetrics and Gynecology, The Jikei University Katsushika Medical Center, Tokyo, Japan . ) , Isonishi, Seiji (Department of Obstetrics and Gynecology, The Jikei University Daisan Hospital, Tokyo, Japan . ) , Takano, Hirokuni (Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa, Japan . ) , Okamoto, Aikou
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e37 , 2018 , 2005-0380 ,

    초록

    Objective The aim of the study is to investigate recurrence of stage I epithelial ovarian cancer. Methods Six hundred two patients diagnosed with stage I epithelial ovarian cancer at 4 hospitals between 2000 and 2013 were retrospectively analyzed. Age, surgical procedure, substage, histologic type, adjuvant chemotherapy, recurrence, initial recurrence site (peritoneal dissemination [P], hematogenous recurrence [H], lymphogenous recurrence [L], and others [O]), and frequency of recurrence at each site were investigated retrospectively. Results Median age was 54 years and median follow-up was 60 months. The stage was IA in 180 cases (30%), IB in 8 (1%), IC1 in 247 (41%), IC2 in 63 (10%), and IC3 in 104 (17%). Systematic lymph node dissection including both pelvic and para-aortic lymph nodes was performed in 224 patients (37%), and 412 patients (68%) received adjuvant chemotherapy. Recurrence occurred in 70 patients (11.6%). The median time to recurrence was 18 months, and the stage was IA in 13 (19%), IB in 1 (1%), IC1 in 24 (34%), IC2 in 9 (13%), and IC3 in 23 (33%) cases. The numbers of recurrence at the P, H, L, and O sites, including overlapping cases, were 49 (70%), 18 (26%), 9 (13%), and 6 (9%), respectively, and recurrence by peritoneal dissemination in the pelvis occurred in 43 cases (61%). Conclusion Recurrence of stage I epithelial ovarian cancer by peritoneal dissemination was frequent, especially in the pelvis. There is a need to elucidate the pathogenesis of peritoneal recurrence and to prepare a treatment strategy to prevent pelvic peritoneal recurrence.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [국내논문]   Gynecologic cancer in Brazil and the law of sixty days   SCIE

    Paulino, Eduardo (Instituto Nacional do Câncer (INCA), Hospital do Câncer II, Santo Cristo, Rio de Janeiro, Brazil . ) , de Melo, André (Instituto Nacional do Câncer (INCA), Hospital do Câncer II, Santo Cristo, Rio de Janeiro, Brazil . ) , ia Cristina (Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil . ) , Nogueira-Rodrigues, Angé (Instituto Nacional do Câncer (INCA), Hospital do Câncer II, Santo Cristo, Rio de Janeiro, Brazil . ) , lica , Thuler, Luiz Claudio Santos
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e44 , 2018 , 2005-0380 ,

    초록

    Objective The aim of the study is to investigate recurrence of stage I epithelial ovarian cancer. Methods Six hundred two patients diagnosed with stage I epithelial ovarian cancer at 4 hospitals between 2000 and 2013 were retrospectively analyzed. Age, surgical procedure, substage, histologic type, adjuvant chemotherapy, recurrence, initial recurrence site (peritoneal dissemination [P], hematogenous recurrence [H], lymphogenous recurrence [L], and others [O]), and frequency of recurrence at each site were investigated retrospectively. Results Median age was 54 years and median follow-up was 60 months. The stage was IA in 180 cases (30%), IB in 8 (1%), IC1 in 247 (41%), IC2 in 63 (10%), and IC3 in 104 (17%). Systematic lymph node dissection including both pelvic and para-aortic lymph nodes was performed in 224 patients (37%), and 412 patients (68%) received adjuvant chemotherapy. Recurrence occurred in 70 patients (11.6%). The median time to recurrence was 18 months, and the stage was IA in 13 (19%), IB in 1 (1%), IC1 in 24 (34%), IC2 in 9 (13%), and IC3 in 23 (33%) cases. The numbers of recurrence at the P, H, L, and O sites, including overlapping cases, were 49 (70%), 18 (26%), 9 (13%), and 6 (9%), respectively, and recurrence by peritoneal dissemination in the pelvis occurred in 43 cases (61%). Conclusion Recurrence of stage I epithelial ovarian cancer by peritoneal dissemination was frequent, especially in the pelvis. There is a need to elucidate the pathogenesis of peritoneal recurrence and to prepare a treatment strategy to prevent pelvic peritoneal recurrence.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [국내논문]   Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study   SCIE

    Ceresoli, Marco (Unit of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Verrengia, Apollonia (Unit of Gynecology, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Montori, Giulia (Unit of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Busci, Luisa (Unit of Gynecology, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Coccolini, Federico (Unit of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Ansaloni, Luca (Unit of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy . ) , Frigerio, Luigi (Unit of Gynecology, Papa Giovanni XXIII Hospital, Bergamo, Italy . )
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e53 , 2018 , 2005-0380 ,

    초록

    Objective Hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as a treatment in ovarian cancer. A recently published RCT demonstrated that HIPEC prolongs disease-free survival (DFS) and overall survival (OS) in ovarian cancer. The aim of the study was to investigate oncologic results of cytoreductive surgery+HIPEC compared with cytoreductive surgery alone in advanced primary ovarian cancer with a particular attention to the pattern of recurrence. Methods This is a retrospective case control study with a propensity score (PS) matching of the patients. All the patients treated for primary advanced ovarian cancer who underwent interval surgery with or without HIPEC were collected; a PS was calculated in order to match cases to controls. Results Among 77 eligible patients 56 patients were included in the study. Preoperative patients' characteristics were homogeneous. No difference in morbidity and mortality after surgery were recorded. DFS was not different among the 2 groups (13.2 vs. 13.9 months, p=0.454) but OS was better in patients treated with HIPEC with no median reached vs. 35.5 months (p=0.048). Patients treated with cytoreductive surgery alone were more likely to have a peritoneal recurrence (43% vs. 14%). Conclusion HIPEC seems to affect the relapse pattern with lesser peritoneal recurrence. This difference in relapse pattern seems to affect the OS with better results in patients treated with HIPEC. Further studies are needed to confirm these findings.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [국내논문]   Endometrial cancer risk and survival by tumor MMR status   SCIE

    Nagle, Christina M. (Population Health Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia . ) , O'Mara, Tracy A. (Genetics & Computational Biology Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia . ) , Tan, Yen (Genetics & Computational Biology Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia . ) , Buchanan, Daniel D. (Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Australia . ) , Obermair, Andreas (Queensland Centre of Gynaecological Research, Royal Brisbane and Women's Hospital, Herston, Australia . ) , Blomfield, Penny (Department of Gynaecology Oncology, Royal Hobart Hospital, Hobart, Australia . ) , Quinn, Michael A. (Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia . <cou) , Webb, Penelope M. , Spurdle, Amanda B.
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e39 , 2018 , 2005-0380 ,

    초록

    Objective The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and the risk of developing EC and survival following a diagnosis of EC. Methods We analyzed data from women who participated in the Australian National Endometrial Cancer Study (ANECS) conducted between 2005 and 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic and lifestyle information obtained from telephone interviews at recruitment. For survival analyses (728 cases), patients' clinical data was abstracted from medical records, and survival data were obtained via linkage with the Australian National Death Index. We used logistic regression analysis to evaluate the associations between tumor MMR status and EC risk, and proportional hazards models to perform survival analyses with adjustment of known prognostic factors. Results Established risk factors for EC did not differ significantly by tumor MMR status. In analyses including all EC subtypes, overall and EC-specific survival did not differ by tumor MMR status. Among women with the most common endometrioid subtype, EC-specific survival was worse for women with somatic MMR-deficient EC compared to women with MMR-proficient EC (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.19–4.01). Conclusion The risk of EC is not associated with MMR status. Accurate separation of germline from somatic causes of MMR deficiency suggests that patients with endometrioid subtype somatic MMR-deficient tumors have poorer EC-specific survival than those with MMR-proficient tumors, after accounting for other prognostic factors.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [국내논문]   Outpatient cervical brachytherapy in the setting of ongoing antiplatelet therapy or oral anticoagulation  

    Valakh, Vladimir (Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, USA. ) , Munns, Stephanie A. (Division of Gynecologic Oncology, Allegheny Health Network, Pittsburgh, PA, USA. ) , Trombetta, Mark G. (Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, USA.)
    Journal of gynecologic oncology : jgo v.29 no.3 , 2018 , 2005-0380 ,

    초록

    Objective The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and the risk of developing EC and survival following a diagnosis of EC. Methods We analyzed data from women who participated in the Australian National Endometrial Cancer Study (ANECS) conducted between 2005 and 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic and lifestyle information obtained from telephone interviews at recruitment. For survival analyses (728 cases), patients' clinical data was abstracted from medical records, and survival data were obtained via linkage with the Australian National Death Index. We used logistic regression analysis to evaluate the associations between tumor MMR status and EC risk, and proportional hazards models to perform survival analyses with adjustment of known prognostic factors. Results Established risk factors for EC did not differ significantly by tumor MMR status. In analyses including all EC subtypes, overall and EC-specific survival did not differ by tumor MMR status. Among women with the most common endometrioid subtype, EC-specific survival was worse for women with somatic MMR-deficient EC compared to women with MMR-proficient EC (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.19–4.01). Conclusion The risk of EC is not associated with MMR status. Accurate separation of germline from somatic causes of MMR deficiency suggests that patients with endometrioid subtype somatic MMR-deficient tumors have poorer EC-specific survival than those with MMR-proficient tumors, after accounting for other prognostic factors.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [국내논문]   Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization   SCIE

    Chang, Hyeyoon (Department of Pathology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea . ) , Hong, Jin Hwa (Department of Obstetrics and Gynecology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea . ) , Lee, Jae-Kwan (Department of Obstetrics and Gynecology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea . ) , Cho, Hyun Woong (Department of Obstetrics and Gynecology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea . ) , Ouh, Yung Taek (Department of Obstetrics and Gynecology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea . ) , Min, Kyung Jin (Department of Obstetrics and Gynecology, Korea University Ansan Hospital, College of Medicine, Korea University, Ansan, Korea . ) , So, Kyeong A (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcar)
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e27 , 2018 , 2005-0380 ,

    초록

    Objective Impaired local cellular immunity contributes to persistent human papillomavirus (HPV) infection and development of cervical intraepithelial neoplasia (CIN). Programmed death-1 (PD-1) and its ligands PD-ligand-1 (L1) and PD-L2 are negative regulators of T cell activity in various cancers, but few studies exist. The aim of this study was to determine the clinicopathologic and immunologic parameters (PD-1, PD-L1, and PD-L2) related to the persistence/recurrence of CIN after conization. Methods Medical records of 652 patients diagnosed with CIN and underwent conization were reviewed. The associations between clinicopathologic parameters (e.g., age, parity, initial HPV load, etc.) and persistence/recurrence of CIN were analyzed. Expression of PD-1, PD-L1, and PD-L2 was assessed on 100 conization specimens by immunohistochemistry (IHC) in women matched for propensity-score (50 with persistence/recurrence and 50 without). Results Initial HPV load (>1,000 relative light unit) and positive margin were shown to be significantly associated with CIN persistence/recurrence (p=0.012 and p Conclusion Positive surgical margin and expression of PD-1+ T cells were associated with CIN persistence/recurrence after conization.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [국내논문]   Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma   SCIE

    Baek, Min-Hyun (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Park, Jeong-Yeol (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Park, Yangsoon (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Kim, Kyu-Rae (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Kim, Dae-Yeon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Suh, Dae-Shik (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Kim, Jong-Hyeok (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea . ) , Kim, Yong-Man (Department) , Kim, Young-Tak , Nam, Joo-Hyun
    Journal of gynecologic oncology : jgo v.29 no.3 ,pp. e30 , 2018 , 2005-0380 ,

    초록

    Objective To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. Methods The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray. Results In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2–28.4 and OR=0.2; 95% CI=0.05–0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR. Conclusion AR can be a potential prognostic biomarker in uterine leiomyosarcoma.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  10. [국내논문]   Diagnostic value of integrated 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients  

    Lee, Young-Jae (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Kim, Yong-Man (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Jung, Phill-Seung (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Lee, Jong-Jin (Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Kim, Jeong-Kon (Department of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Kim, Young-Tak (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. ) , Nam, Joo-Hyun (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.)
    Journal of gynecologic oncology : jgo v.29 no.3 , 2018 , 2005-0380 ,

    초록

    Objective To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. Methods The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray. Results In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2–28.4 and OR=0.2; 95% CI=0.05–0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR. Conclusion AR can be a potential prognostic biomarker in uterine leiomyosarcoma.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지